Invesco Ltd. Has $71.51 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Invesco Ltd. boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,699,756 shares of the biopharmaceutical company's stock after buying an additional 25,487 shares during the quarter. Invesco Ltd. owned approximately 1.84% of Ultragenyx Pharmaceutical worth $71,509,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in RARE. Smartleaf Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 493 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter worth approximately $35,000. Human Investing LLC acquired a new position in Ultragenyx Pharmaceutical during the 4th quarter valued at approximately $42,000. Van ECK Associates Corp grew its stake in Ultragenyx Pharmaceutical by 18.4% during the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 273 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Ultragenyx Pharmaceutical in the third quarter worth $83,000. 97.67% of the stock is currently owned by institutional investors.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, insider John Richard Pinion sold 14,439 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $607,881.90. Following the completion of the transaction, the insider now directly owns 107,766 shares in the company, valued at $4,536,948.60. The trade was a 11.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Howard Horn sold 1,785 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the sale, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. The trade was a 1.65 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 124,643 shares of company stock worth $5,256,268. Company insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Stock Up 2.0 %

Shares of NASDAQ:RARE traded up $0.71 on Friday, reaching $35.69. The company had a trading volume of 690,760 shares, compared to its average volume of 808,102. The stock has a market capitalization of $3.35 billion, a P/E ratio of -5.63 and a beta of 0.61. The stock has a 50-day moving average price of $38.41 and a 200 day moving average price of $44.26. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.59 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RARE has been the subject of several recent research reports. Piper Sandler lowered their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Monday, March 17th. Canaccord Genuity Group raised their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. HC Wainwright reissued a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Finally, Wells Fargo & Company raised their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research note on Friday, December 20th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $92.79.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.